(Please see Prescribing Information, including Boxed Warning, about increased risk of tendinitis and tendon rupture and exacerbation of muscle weakness in patients with myasthenia gravis.)
(Please see Prescribing Information, including Boxed Warning, about increased risk of tendinitis and tendon rupture and exacerbation of muscle weakness in patients with myasthenia gravis.)
NuvaRing® (etonogestrel/ethinyl estradiol vaginal ring) delivers 0.120 mg/0.015 mg per day (Please read the Boxed Warning about serious cardiovascular events, especially in women who smoke, in the Prescribing Information.)
Signing in using the form to the left will give you access to this service for other products.
No educational resources related to NuvaRing® (etonogestrel/ethinyl estradiol vaginal ring) delivers 0.120 mg/0.015 mg per day are available at this time.
You can request a number of complimentary resources, where available, including:
NuvaRing is indicated for the prevention of pregnancy in women.
SELECTED SAFETY INFORMATION
Cigarette smoking increases the risk of serious cardiovascular side effects from combination oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use combination hormonal contraceptives, including NuvaRing should be strongly advised not to smoke.
• The use of combination oral contraceptives is associated with increased risks of several serious side effects, including stroke or heart attack. NuvaRing is not for women with a history of these conditions. Combination oral contraceptives are also associated with increased risk of thromboembolic diseases. Some studies suggest that this risk is increased by combination oral contraceptives containing desogestrel; additional studies do not support this finding. It is unknown whether NuvaRing has a different risk of venous thromboembolism (VTE) than second-generation oral contraceptives.
• NuvaRing is not for women with certain cancers or those who may be pregnant.
• NuvaRing does not protect against HIV infection and other sexually transmitted diseases.
• The most common adverse events reported by 5% to 14% of women using NuvaRing in clinical trials (n=2501) were vaginitis, headache, upper respiratory tract infection, vaginal secretion, sinusitis, weight gain, and nausea.
All product names listed on this site are registered trademarks owned by or licensed to a subsidiary of Merck & Co., Inc.
MerckProductServices, MerckServices, MerckSource, Merck OnCall, MerckMedicus, and MerckEngage are trademarks or registered trademarks of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Product Samples
Signing in using the form to the left will give you access to this service for other products.
You can request complimentary samples of Merck products for your patients.
eMedical Forum Webcasts
Please sign in using the form to the left to access this service.
Upcoming Webcasts
No live medical forum webcasts are currently available.
To view the details of upcoming webcasts that you have registered for, sign in now in the upper left corner of the page.
Archived Webcasts
Archived webcasts can be viewed at any time.
Sign in to access our archived eMedical Forum Webcasts, which are available for your viewing at any time.
